Search Clinical Trials
597,783 trials
ID
Status
Phase
Title
Sponsor
NCT07758023
Achieving Optimal Medical Therapy Through Percutaneous Treatment of Secondary Mitral Regurgitation to Improve Outcome in Patients With HFrEFAbbottNot Yet RecruitingNot Applicable
NCT07758023Not Yet Recruiting
Not Applicable
Achieving Optimal Medical Therapy Through Percutaneous Treatment of Secondary Mi...Abbott
NCT07757958
Partial Breast Irradiation Without Sentinel Lymph Node Biopsy in Low-Risk Early Breast CancerNational Institute of Health, KoreaNot Yet RecruitingPhase 3
NCT07757958Not Yet Recruiting
Phase 3
Partial Breast Irradiation Without Sentinel Lymph Node Biopsy in Low-Risk Early...National Institute of Hea...
NCT07758907
Interference and Stability Evaluation of the Intelligent Fingerprinting Drug Screening SystemCenExelEnrolling By InvitationNot Applicable
NCT07758907Enrolling By Invitation
Not Applicable
Interference and Stability Evaluation of the Intelligent Fingerprinting Drug Scr...CenExel
NCT07757789
Thrombocytopenia Trajectories in Antiphospholipid Syndrome: A Multicenter Cohort StudyNew Valley UniversityRecruitingNot Applicable
NCT07757789Recruiting
Not Applicable
Thrombocytopenia Trajectories in Antiphospholipid Syndrome: A Multicenter Cohort...New Valley University
NCT07757009
Perioperative Forced-Air Warming During Elective Cesarean Delivery Under Spinal AnesthesiaHamad Medical CorporationCompletedNot Applicable
NCT07757009Completed
Not Applicable
Perioperative Forced-Air Warming During Elective Cesarean Delivery Under Spinal...Hamad Medical Corporation
NCT07758621
SYS6010 vs Investigator's Choice of Monotherapy in Patients With Recurrent or Metastatic HNSCCCSPC Megalith Biopharmaceutical Co.,Ltd.Not Yet RecruitingPhase 3
NCT07758621Not Yet Recruiting
Phase 3
SYS6010 vs Investigator's Choice of Monotherapy in Patients With Recurrent or Me...CSPC Megalith Biopharmace...
NCT07757373
Romosozumab Versus Denosumab In Glucocorticoid-induced Osteoporosis: An Extended Observation Of a Randomized Controlled Trail At 6 YearsTuen Mun HospitalNot Yet RecruitingPhase 4
NCT07757373Not Yet Recruiting
Phase 4
Romosozumab Versus Denosumab In Glucocorticoid-induced Osteoporosis: An Extended...Tuen Mun Hospital
NCT07758816
Advancing Integrated Therapies for Gaucher DiseaseSanofi-Yale External Research CollaborationRecruiting
NCT07758816Recruiting
—
Advancing Integrated Therapies for Gaucher DiseaseSanofi-Yale External Rese...
NCT07758920
A Clinical Trial to Evaluate the Efficacy and Safety of HL-1186 Tablet in the Treatment of Postherpetic NeuralgiaShanghai Yidian Pharmaceutical Technology Development Co., Ltd.RecruitingPhase 2
NCT07758920Recruiting
Phase 2
A Clinical Trial to Evaluate the Efficacy and Safety of HL-1186 Tablet in the Tr...Shanghai Yidian Pharmaceu...
NCT07757568
Prospective Evaluation of De-Escalation From antiCD-20 Therapies to Dimethyl Fumarate (Tecfidera) or Diroximel Fumarate (Vumerity)University of Colorado, DenverActive Not Recruiting
NCT07757568Active Not Recruiting
—
Prospective Evaluation of De-Escalation From antiCD-20 Therapies to Dimethyl Fum...University of Colorado, D...
NCT07757971
2D:4D Ratio in Relation to Anxiety and Stress Among Anesthesiology ResidentsAin Shams UniversityNot Yet Recruiting
NCT07757971Not Yet Recruiting
—
2D:4D Ratio in Relation to Anxiety and Stress Among Anesthesiology ResidentsAin Shams University
NCT07758504
Comparison of Performing V-Notes Hysterectomy Under Spinal Anesthesia and General AnesthesiaCukurova UniversityNot Yet RecruitingNot Applicable
NCT07758504Not Yet Recruiting
Not Applicable
Comparison of Performing V-Notes Hysterectomy Under Spinal Anesthesia and Genera...Cukurova University
NCT07757282
Peripheral Blood Lipidomic and Ceramide Profiles in Atrial FibrillationFirst Affiliated Hospital Xi'an Jiaotong UniversityRecruiting
NCT07757282Recruiting
—
Peripheral Blood Lipidomic and Ceramide Profiles in Atrial FibrillationFirst Affiliated Hospital...
NCT07757672
Salvage Chemotherapy With Sonrotoclax, Cladribine, and Standard-dose Cytarabine, Sequentially Followed by HSCT for R/R AML.Institute of Hematology & Blood Diseases Hospital, ChinaNot Yet RecruitingPhase 1
NCT07757672Not Yet Recruiting
Phase 1
Salvage Chemotherapy With Sonrotoclax, Cladribine, and Standard-dose Cytarabine,...Institute of Hematology &...
NCT07756671
Photodynamic Therapy For OnychomycosisThe University of Texas Health Science Center, HoustonNot Yet RecruitingPhase 1
NCT07756671Not Yet Recruiting
Phase 1
Photodynamic Therapy For OnychomycosisThe University of Texas H...
NCT07757685
Autologous Hematopoietic Stem Cell Transplantation for Neurological Damage Associated With Hereditary Homocysteine Remethylation DisordersInstitute of Hematology & Blood Diseases Hospital, ChinaNot Yet RecruitingNot Applicable
NCT07757685Not Yet Recruiting
Not Applicable
Autologous Hematopoietic Stem Cell Transplantation for Neurological Damage Assoc...Institute of Hematology &...
NCT07757867
Microneedling-Assisted Delivery of Cetirizine Versus Latanoprost in Alopecia AreataTanta UniversityCompletedNot Applicable
NCT07757867Completed
Not Applicable
Microneedling-Assisted Delivery of Cetirizine Versus Latanoprost in Alopecia Are...Tanta University
NCT07758595
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL921 in Healthy Participants and Participants With Alzheimer's DiseaseDenali Therapeutics Inc.Not Yet RecruitingPhase 1
NCT07758595Not Yet Recruiting
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL921...Denali Therapeutics Inc.
NCT07758647
NO-Meal Announcement in Automated Insulin Delivery (Open-source and Commercial) SystemsInstitut de Recherches Cliniques de MontrealNot Yet RecruitingNot Applicable
NCT07758647Not Yet Recruiting
Not Applicable
NO-Meal Announcement in Automated Insulin Delivery (Open-source and Commercial)...Institut de Recherches Cl...
Result Breakdown
Not yet recruiting11 (55%)
Recruiting4 (20%)
Completed3 (15%)
Enrolling by invitation1 (5%)
Active, not recruiting1 (5%)
not_applicable9 (45%)
Not Specified4 (20%)
Phase 13 (15%)
Phase 32 (10%)
Phase 41 (5%)
Phase 21 (5%)